A hematopoietic stem cell transplant is not a single procedure but a chain of stages spread over weeks. Chemotherapy and growth factors push stem cells from the marrow into the bloodstream (mobilization); an apheresis machine collects those cells over several sessions; the cells are frozen and stored (cryopreservation); high-dose chemotherapy empties the marrow (conditioning); and finally the cells are reinfused, followed by the wait for engraftment. To a patient it is one treatment. To an insurance reviewer, each stage may sit in a different box — which is why a hospital stay for cell collection is sometimes questioned.
The first axis is the wording of the policy itself. Newer standardized cancer policies in Korea tend to spell out what counts as direct treatment of cancer, generally listing surgery, chemotherapy, radiotherapy, and stem cell transplantation performed for those purposes. Older contracts often use shorter, broader language, leaving far more room for differing interpretations between companies. The starting point is therefore not a web search but the actual clause in the version of the policy that applied when the contract was signed.
The second axis is the purpose of admission. An admission for diagnostic testing, one for managing side effects, and one that forms part of the treatment plan itself read differently on paper. Collection is not chemotherapy infusion in itself, but it is a mandatory step toward completing the transplant — and what matters is whether the discharge summary states that purpose plainly.
The third axis is medical necessity: could this have been done as an outpatient? Central venous catheter placement, the chemotherapy and growth factors used for mobilization, monitoring for reactions such as low calcium during apheresis, and infection management during neutropenia are all reasons that belong in the record if they applied.
The fourth axis is whose admission it was. In allogeneic transplantation, a donor admitted for collection is not covered under the patient's own contract — unlike autologous transplantation, where the patient's own cells are collected.
If you decide to contest the decision, work in order. Ask for the denial reason in writing rather than by phone. Retrieve the policy number, enrollment date, and the relevant clause from that era. Obtain the itemized billing statement showing exactly which procedures and drugs were involved. Ask the treating physician for a statement explaining that the admission was a necessary step in the transplant plan and could not reasonably have been done on an outpatient basis. Then request a formal reassessment, and if the disagreement persists, use the financial supervisory dispute mediation process. Keep an eye on the claim's statute of limitations so dates do not quietly expire.
This article is general information and does not replace individual medical or contractual advice. Please discuss treatment schedules, tests, and any changes in your condition with your care team, and confirm coverage questions against your own policy documents and with your insurer or the relevant supervisory body.